Answers are grounded in this paper and cite their sources.
Mycophenolate mofetil (MMF) is an immunosuppressive drug the efficiency of which has been established in renal transplantation. Recent studies suggest that it may also be effective in the treatment of variant skin diseases especially if the skin lesions are triggered by lymphocytes. Studies have shown efficacy in autoimmune bullous dermatoses, atopic dermatitis and psoriasis. However, there are no placebo-controlled trials that support the use of MMF as first line therapy in these skin diseases.
No takes yet. Share an insight, caveat, or question.
Hartmann et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: